SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
2026年4月26日 更新者:Limin Liu,MD、The First Affiliated Hospital of Soochow University
A Prospective, Multicenter, Open-label, Randomized Controlled Trial of SHR2554 Plus Azacitidine in Overlapped Sequential Combination With TBF Conditioning Regimen in Patients With High-risk or Relapsed/Refractory Acute Leukemia and Myelodysplastic Neoplasms
This study was designed as a prospective, multicenter, open-label, randomized controlled trial.
Eligible participants were patients aged 15-60 years with high-risk or relapsed/refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic neoplasms (MDS), diagnosed based on bone marrow morphology, immunophenotyping, genetic testing, and treatment response assessment.
The experimental group received SHR2554 combined with azacitidine as an overlapped sequential combination with the TBF conditioning regimen, whereas the control group received the mBuCy conditioning regimen, both followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).
The primary endpoint was the 2-year cumulative incidence of relapse (CIR) after allo-HSCT.
Secondary endpoints included 2-year overall survival (OS), 2-year disease-free survival (DFS), transplant-related mortality (TRM), the incidence of acute and chronic graft-versus-host disease (GVHD), and safety profiles.
研究概览
地位
尚未招聘
研究类型
介入性
注册 (估计的)
160
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:LIMIN LIU, MD
- 电话号码:+86-512-6778183
- 邮箱:Liminliu1006@163.com
学习地点
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215006
- The First Affiliated Hospital of Soochow University
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
- 成人
接受健康志愿者
不
描述
Inclusion Criteria:
- Age 15-60 years, of either sex.
- Diagnosis of AML or ALL according to the WHO 2022 criteria, with an indication for allogeneic hematopoietic stem cell transplantation: AML with high-risk genetics at diagnosis (risk stratification per ELN 2022) or relapsed/refractory AML (meeting any of the following: refractory-failure to achieve complete remission (CR) after two cycles of induction chemotherapy; relapse-reappearance of blasts in peripheral blood or bone marrow (≥5%) after first CR, or extramedullary relapse (EMR)). High-risk B-ALL at diagnosis (risk stratification per ELN 2022) or pre-transplant MRD-positive B-ALL. Confirmed T-ALL. History of central nervous system leukemia (CNSL) or pathologically confirmed extramedullary disease (EMD) during AML or ALL. Myelodysplastic neoplasms (MDS): IPSS score intermediate-2 or high; IPSS-R score high or very high; IPSS-M score high or very high.
- Availability of an appropriate HLA-matched donor.
- ECOG performance status 0-2.
- Adequate major organ function, defined as: Left ventricular ejection fraction ≥50%. Pulmonary function: DLCO ≥50% of predicted value. Liver function: ALT/AST ≤3×ULN, total bilirubin ≤2×ULN. Renal function: estimated creatinine clearance (CrCl) ≥60 mL/min.
- Ability to understand the study and voluntary signed informed consent.
Exclusion Criteria:
- Acute promyelocytic leukemia (APL);
- Active central nervous system leukemia;
- Prior allogeneic hematopoietic stem cell transplantation;
- Prior treatment with any EZH2 inhibitor;
- Uncontrolled active infection as assessed by the investigator;
- Myocardial infarction or unstable angina within the previous 6 months;
- Known hypersensitivity to Zeprumetostat, azacitidine, or any excipient of the mBuCy regimen;
- Pregnant or breastfeeding women;
- Any other medical condition that, in the investigator's judgment, would preclude study enrollment.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SHR2554/AZA + Overlapped TBF
SHR2554 350 mg BID and azacitidine 75 mg/m² daily on days -9 to -3, overlapping with TBF conditioning: thiotepa 5 mg/kg on days -8 and -7; cytarabine 2 g/m² q12h on day -6; busulfan 0.8 mg/kg q6h on days -5, -4, -3 (total 3.2 mg/kg/day); fludarabine 30 mg/m²/day on days -6 to -2.
|
SHR2554/AZA + Overlapped TBF conditioning Regimen and GVHD Prophylaxis of Haploid transplantation (Haplo-HSCT) and unrelated donor transplantation (UDT) : Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG) or GVHD Prophylaxis of Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD-HSCT):Cyclosporine A (CsA) + short-term low-dose methotrexate (MTX), then stem cells are infused into patient's blood.
其他名称:
|
|
有源比较器:mBUCY conditioning Regimen Group
semustine 250 mg/m² on day -8; cytarabine 2 g/m² q12h on day -7; busulfan 0.8 mg/kg q6h on days -6, -5, -4 (total 3.2 mg/kg/day); cyclophosphamide 1.8 g/m²/day on days -3 and -2.
|
MBucy调节方案和GVHD的单倍移植(HAPLO-HSCT)和无关供体移植(UDT):环孢霉素A(CSA) +霉菌甲酸肉豆蔻酸酯Mofetil spereresible Tables(MMF)人抗杀菌细胞球蛋白(ATG)或GVHD预防匹配的同胞供体造血干细胞移植(MSD-HSCT):环孢素A(CSA) +短期低剂量甲氨蝶呤(MTX),然后将干细胞注入患者的血液中。
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
复发的累积发生率(CIR)
大体时间:2年
|
记录了从移植后完全缓解到血液复发或分子复发的日期。
在上次随访中没有复发的患者被视为审查数据,而非释放死亡被认为是竞争风险事件。
|
2年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
总生存期(OS)
大体时间:2年
|
从进入本试验之日起至因任何原因死亡之日计算;在最后一次随访中不知道已经死亡的患者在他们最后一次知道还活着的日期被审查。
|
2年
|
|
造血重建的时间段
大体时间:24周
|
颗粒发育造血重建:外周血中的绝对中性粒细胞计数需要连续3天达到或超过0.5×10^9细胞/L。
巨型造血造血重构:血小板计数必须超过20×10^9/L,并且连续7天不依赖血小板输血。
|
24周
|
|
graft-versus-host disease (GvHD)
大体时间:2 years
|
incidence and severity of acute (aGvHD) and chronic graft-versus-host disease (cGvHD) (aGvHD refer to Glucksberg Criteria and cGvHD refer to the National Institutes of Health Consensus)
|
2 years
|
|
Disease-free survival(DFS)
大体时间:2 years
|
It is measured from the time from randomization to the first of relapse or death.
|
2 years
|
|
transplant related mortality (TRM)
大体时间:2 years
|
cumulative incidence of transplant related mortality
|
2 years
|
|
Regimen related toxicity
大体时间:2 years
|
Number of participants with regimen related toxicity as assessed by CTCAE v5.0
|
2 years
|
|
veno-occlusive disease (VOD)
大体时间:2 years
|
incidence of veno-occlusive disease (VOD) events (refer to modified Seattle Criteria of VOD)
|
2 years
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年6月1日
初级完成 (估计的)
2030年6月1日
研究完成 (估计的)
2030年6月1日
研究注册日期
首次提交
2026年4月26日
首先提交符合 QC 标准的
2026年4月26日
首次发布 (实际的)
2026年5月1日
研究记录更新
最后更新发布 (实际的)
2026年5月1日
上次提交的符合 QC 标准的更新
2026年4月26日
最后验证
2026年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.